Inovio Pharma (INO) Tops Q4 EPS by 6c, Beats on Revenues
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.18 -0.84%
EPS Growth %: +60.7%
Financial Fact:
Total revenue: 12.54M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: +60.7%
Financial Fact:
Total revenue: 12.54M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Note: EPS may not be comparable
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $7.53 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP
- Raymond James Previews Charles Schwab Corp. (SCHW) Earnings: 'Elevated Trading Volumes Drives Trading Revenue Upside'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
